Publications and Presentations of the Tuberculosis Trials Consortium (2011-2016)  
October 3, 2016

I. Publications

2016

Study 34 - ACTG 5295  

Study 26 - Non-completion Treatment  
Factors Associated with Non-completion of Latent Tuberculosis Infection Treatment: Experience from the PREVENT TB Trial in the United States and Canada. Clinical Infectious Disease, 2016.

Study 26 - HIV Seropositive  

2015

Study 26A  

S29: Evaluation of Consent Process  

Study 29X  

Study 29 - Biomarkers  

Study 26HS  

Study 26 - TB Pediatric  

2014

Study 29PK/29X PK  

NAA2m  


2013


2012


Study 29

Study 29 - Biomarkers

Study 28

Study 30

2011

Study 30

Study 28 - Africa
difference

Study 29 - Biomarkers

Study 26 - Main

Selected Guideline Publications Influenced by TBTC Work


II. Presentations and Abstracts

2016

Study 33- Cost Effectiveness  

Early treatment response in adult TB/HIV patients, Soweto  

Study 26  
Pregnancy  

2015

ALT kinetic biomarker for hepatotoxicity  

S33 Motivations to Enroll  

Study 34 - ACTG 5295  

Study 26 - Non-completion Treatment  

Studies 27, 28, 29, 29X Adverse Events  

Study 33- I Adhere  

Study 33- I Adhere  

Markers of Trx response in children, Stellenbosch & Kisumu  
2014

Study 29 - GeneXpert


S33

Motivations to Enroll


Study 34 - ACTG 5295


ALT kinetic biomarker for hepatotoxicity


Study 29 - GeneXpert


Study 26 - Non-completion Treatment


Study 26 - Non-completion Treatment


Studies 27, 28, 29, 29X

Adverse Events


Study 26 - HIV Seropositive


2013


Kolwijck E, Friedrich SO, Venter A, van Ingen J, Diacon AH. Effect of culture supernatant containing resuscitation-promoting factors on the growth of M. tuberculosis from sputum samples collected during antituberculosis treatment. European Society for Clinical Microbiology and Infectious Diseases, April 27-30, 2013, Berlin, Germany.


Dooley K and Bliven-Sizemore E. Population pharmacokinetics of pyrazinamide. Presented at the Clinical Pharmacology of TB Drugs meeting, Sept 2013


Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. 6th International Workshop on Clinical Pharmacology of TB Drugs, Sept 2013

Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. Gates sponsored TB Modeling and Analysis Consortium meeting in Beijing, China

Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. CPTR meeting in Washington, DC - October, 2013

Dorman S and Goldberg S. Study 29X, Phase 2 clinical trial, is to compare tolerability and safety of arms containing escalating doses of rifapentine. Presentation, INTER-TB, St. George's University, 25 October 2013

Dorman S and Goldberg S. Study 29X, Phase 2 clinical trial, is to compare tolerability and safety of arms containing escalating doses of rifapentine. Presentation, International Union Against Tuberculosis and Lung Disease, November 2013

2012


Sterling TR, Benson CA, Shang N, Villarino ME, the AIDS Clinical Trials Group, and the Tuberculosis Trials Consortium. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). International AIDS Society, July 2012.


Sterling TR, Benson CA, Shang N, Villarino ME, the AIDS Clinical Trials Group, and the Tuberculosis Trials Consortium. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). IV Congreso Nacional de Gesida, Spain, November 2012.

2011


